Celldex Therapeutics | CLDX

Stock Price
22.87
Daily Change
0.09 0.40%
Monthly
6.67%
Yearly
-47.74%
Q3 Forecast
22.68

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Celldex Therapeutics 22.87 0.09 0.40% -47.74% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Celldex Therapeutics traded at $22.87 this Friday September 5th, increasing $0.09 or 0.40 percent since the previous trading session. Looking back, over the last four weeks, Celldex Therapeutics gained 6.67 percent. Over the last 12 months, its price fell by 47.74 percent. Looking ahead, we forecast Celldex Therapeutics to be priced at 22.68 by the end of this quarter and at 22.12 in one year, according to Trading Economics global macro models projections and analysts expectations.

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.